Analysis of the electrophysiological effects of ambasilide, a new antiarrhythmic agent, in canine isolated ventricular muscle and Purkinje fibers

General Pharmacology

Volumn 34, Issue 2, 2000, Pages 85-93

  Baláti, Beáta ^a   Iost, Norbert ^a   Simon, Judit ^a   Varró, András ^a   Papp, Julius Gy ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Action potential; Ambasilide; Heart muscle

Indexed keywords

AMBASILIDE; LU 47710;

ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; ELECTROPHYSIOLOGY; FEMALE; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART STIMULATION; MALE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PURKINJE FIBER;

ACTION POTENTIALS; AMINOBENZOIC ACIDS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; DOGS; FEMALE; HEART; HEART VENTRICLES; KINETICS; MALE; MICROELECTRODES; PAPILLARY MUSCLES; PURKINJE FIBERS;

EID: 0343826073     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(00)00048-3     Document Type: Article

References (33)

1. Antzelevitch C., Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. the role of M cells in the generation of U waves, triggered activity and torsade de pointes J Am Coll Cardiol. 23:1994;259-277.
2. Antzelevitch C., Sun Z.Q., Zhang Z.Q.et al. Cellular and ionic mechanisms underlying erythromycin-induced long QT and torsade de pointes. J Am Coll Cardiol. 28:1996;1836-1848.
3. Attwell D., Cohen I., Eisner D., Ohba M., Ojeda C. The steady-state tetrodotoxin-sensitive ("window") sodium current in cardiac Purkinje fibers. Pfluegers Arch. 379:1979;137-142.
4. Cardiac Arrhythmia Suppression Trial (CAST) Investigators, 1989. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321, 406-412.
5. max) in guinea pig ventricular action potentials by mexiletine, disopyramide, and encainide. J Cardiovasc Pharmac. 5:1983;291-296. a.
6. Campbell T.J. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res. 17:1983;344-352. b.
7. Carmeliet E. Slow inactivation of the sodium current in rabbit cardiac Purkinje fibers. Pfluegers Arch. 408:1987;18-26.
8. Colatsky T.J., Follmer C.H., Starmer C.F. Channel specificity in antiarrhythmic drug action. mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias Circulation. 82:1990;2235-2242.
9. Feng J., Wang Z., Li G.R., Nattel S. Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes. J Pharmac Exp Ther. 281:1997;384-392.
10. Follmer C.H., Zhang Z., Singh B.N. Ambasilide. a novel class III compound with a differential effect on repolarization in ventricular muscle and Purkinje fibers Singh B.N., Wellens H.J.J., Hiraoka M. Electropharmacological control of cardiac arrhythmias. 1994;611-627 Futura, Mount Kisco, NY.
11. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential but have a long way to go. reduced effectiveness and dangers of reverse use dependence Circulation. 81:1990;689-690.
12. Koidl B., Flaschberger P., Schaffer P.et al. Effects of the Class III antiarhythmic drug ambasilide on outward currents in human atrial myocytes. Naunyn-Schmiedeberg's Arch Pharmac. 353:1996;226-232.
13. Link M.S., Homoud M., Foote C.B., Wang P.J., Estes N.A. III Antiarrhythmic drug therapy for ventricular arrhythmias. current perspectives J Cardiovasc Electrophysiol. 7:1996;653-670.
14. Lynch J.J. Jr., Sanguinetti M.C., Kimura S., Basset A.L. Therapeutic potential of modulating potassium currents in the diseased myocardium. FASEB J. 6:1992;2952-2960.
15. Mason J.W., ESWEM Investigators A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 329:1993;452-458.
16. Nattel S., Talajic M. Recent advances in understanding the pharmacology of amiodarone. Drugs. 36:1988;121-131.
17. Papp J.G., Németh M., Krassói I., Mester L., Hála O., Varró A. Differential electrophysiological effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Cardiovasc Pharmac Ther. 1:1996;287-296.
18. Podrid P.J. Amiodarone. reevaluation of an old drug Ann Intern Med. 122:1995;689-700.
19. Roden D.M., Hoffman B.F. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. relationship to potassium and cycle length Circ Res. 56:1985;857-867.
20. Schreieck J., Wang Y., Gjini V., Korth M., Zrenner B., Schömig A., Schmitt C. Differential effect of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new Class III antiarrhythmics dofetilide, ambasilide,and chromanol 293B. J Cardiovasc Electrophysiol. 8:1997;1420-1430.
21. Sicouri S., Moro S., Litovsky S., Elizari M., Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol. 8:1997;1269-1279.
22. Singh B.N. Controlling cardiac arrhythmias by lengthening repolarization. historical overview Am J Cardiol. 72:1993;18F-24F.
23. Singh B.N. Expanding indications for the use of Class III agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol. 6:1995;887-900.
24. Surawicz B. Electrophysiologic substrate of torsade de pointes. dispersion of repolarization or early afterdepolarizations? J Am Coll Cardiol. 14:1989;172-184.
25. Takanaka C., Sarma J.S.M., Singh B.N. Electrophysiologic effects of ambasilide (LU47110), a novel Class III agent, on the properties of isolated rabbit and canine cardiac muscle. J Cardiovasc Pharmac. 19:1992;290-298.
26. The Sicilian gambit. a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms Circulation. 84:1991;1831-1851.
27. max of action potential upstroke in canine cardiac Purkinje fibres. J Cardiovasc Pharmac. 7:1985;482-492. a.
28. max in cardiac Purkinje and ventricular muscle fibers. Eur J Pharmac. 112:1985;419-422. b.
29. Vaughan-Williams E.M. Classification of antiarrhythmic drugs. Sandoe E., Flensted-Jensen E., Olesenk E. The heart and cardiovascular system. 1981;1203-1238 Raven Press, New York.
30. Waldo A.L., Camm A.J., deRuyter H.et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. the SWORD investigators Lancet. 348:1996;7-12.
31. Weyerbrock S., Schreieck J., Karch M., Overbeck M., Meisner H., Kemkes B., Schömig A., Schmitt C. Rate-independent effects of the new Class III antiarrhythmic agent ambasilide on transmembrane action potentials in human ventricular endomyocardium. J Cardiovasc Pharmac. 30:1997;571-575.
32. Yabek S.M., Kato R., Singh B.N. Effects of amiodarone and its metabolite, desethylamiodarone, on the electrophysiologic properties of isolated cardiac muscle. J Cardiovasc Pharmac. 8:1986;197-203.
33. Zhang Z.H., Follmer C.H., Sarma J.S.M., Chen F., Singh B.H. Effect of ambasilide, a new Class III agent, on plateau currents in isolated guinea pig ventricular myocytes. block of delayed outward potassium current J Pharmacol Exp Ther. 263:1992;40-48.